Key insights
- SciSparc's subsidiary, NeuroThera Labs, filed a patent in Hong Kong for a depression treatment combining MEAI and PEA. While the company shows revenue growth, its stock is down significantly. InvestingPro suggests undervaluation and potential profitability. The news itself has a slightly negative influence as the company is very small and the market capitalization is very low.
TEL AVIV, Israel - SciSparc Ltd. (NASDAQ:SPRC) announced today that NeuroThera Labs Inc. (TSXV:NTLX), in which SciSparc holds approximately 75%, has filed a patent application in Hong Kong, China, for a combination therapy to treat major depressive disorder. The stock currently trades at $4.36 with a market capitalization of $2.47 million, down 94% over the past year despite revenue growth of 188% in the last twelve months as of Q3 2025.
The patent application was filed by Clearmind Medicine Inc. through its collaboration with NeuroThera, according to a press release statement. The therapy combines Clearmind’s 5-methoxy-2-aminoindane (MEAI) with Palmitoylethanolamide (PEA) sourced by NeuroThera.
The World Health Organization reported in August 2025 that depression affects more than 332 million people globally.
SciSparc is a clinical-stage pharmaceutical company that develops cannabinoid-based pharmaceuticals through its majority-owned subsidiary NeuroThera Labs Inc. According to InvestingPro analysis, the company appears undervalued at current levels and analysts predict profitability this year. For investors seeking similar opportunities, the platform’s most undervalued stocks list offers additional prospects. The company’s current drug development programs include SCI-110 for Tourette syndrome, Alzheimer’s disease and agitation, and SCI-210 for autism spectrum disorder and status epilepticus, based on THC and non-psychoactive CBD.
NeuroThera Labs Inc. is a clinical-stage pharmaceutical company focused on developing therapeutics for central nervous system disorders through collaborations and innovative combinations. The company also owns a controlling interest in a subsidiary that sells hemp seed oil-based products on Amazon.com.
In other recent news, SciSparc Ltd. has announced that its subsidiary, NeuroThera Labs Inc., published an international patent application for a novel combination therapy aimed at weight loss and liver disease treatment. This development is part of NeuroThera’s collaboration with Clearmind Medicine Inc. Additionally, NeuroThera Labs has entered into an agreement to acquire a 54.01% stake in CliniQuantum Ltd., a quantum technology firm, by issuing 56,600,000 common shares valued at approximately $9.5 million.
SciSparc Ltd. also reported the implementation of a one-for-nine reverse stock split, reducing its outstanding shares significantly. In another strategic move, SciSparc’s majority-owned subsidiary, NeuroThera Labs, has been granted a U.S. patent for its innovative antibiotic-enhancing cannabinoid technology. This patent aims to improve the efficacy of existing antibiotics against resistant bacterial strains like MRSA.
Furthermore, SciSparc has completed the acquisition of an intellectual property portfolio, including the MUSE system, to enter the gastroesophageal reflux disease (GERD) device market. These recent developments highlight SciSparc’s active engagement in expanding its technological and therapeutic portfolio.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.